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Abstract
Purpose—At the present time, the method of choice to determine surface contamination of the 
workplace with antineoplastic and other hazardous drugs is surface wipe sampling and subsequent 
sample analysis with a variety of analytical techniques. The purpose of this article is to review 
current methodology for determining the level of surface contamination with hazardous drugs in 
healthcare settings and to discuss recent advances in this area. In addition it will provide some 
guidance for conducting surface wipe sampling and sample analysis for these drugs in healthcare 
settings.
Methods—Published studies on the use of wipe sampling to measure hazardous drugs on 
surfaces in healthcare settings drugs were reviewed. These studies include the use of well-
documented chromatographic techniques for sample analysis in addition to newly evolving 
technology that provides rapid analysis of specific antineoplastic
Results—Methodology for the analysis of surface wipe samples for hazardous drugs are 
reviewed, including the purposes, technical factors, sampling strategy, materials required, and 
limitations. The use of lateral flow immunoassay (LFIA) and fluorescence covalent microbead 
immunosorbent assay (FCMIA) for surface wipe sample evaluation is also discussed.
Conclusions—Current recommendations are that all healthcare settings where antineoplastic 
and other hazardous drugs are handled include surface wipe sampling as part of a comprehensive 
hazardous drug-safe handling program. Surface wipe sampling may be used as a method to 
characterize potential occupational dermal exposure risk and to evaluate the effectiveness of 
implemented controls and the overall safety program. New technology, although currently limited 
in scope, may make wipe sampling for hazardous drugs more routine, less costly, and provide a 
shorter response time than classical analytical techniques now in use.
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Occupational exposure to antineoplastic and other hazardous drugs is a concern for 
healthcare facilities in the U.S. and worldwide. Workplace contamination with these drugs, 
especially antineoplastic drugs, is a continuing issue in places where these drugs are 
prepared and administered to patients (Davis et al. 2011). At the present time, surface wipe 
sampling is used to determine the level of workplace contamination in healthcare settings 
where antineoplastic and other hazardous drugs are present (Connor et al. 2016). Wipe 
sampling can help identify the need for and effectiveness of engineering controls, the effect 
of improved work practice controls, and what type of personal protective equipment (PPE) is 
required (Ashley et al. 2011).
In healthcare settings, dermal uptake is considered the most likely route of occupational 
exposure to most hazardous drugs, especially low-molecular-weight antineoplastic drugs. 
Wipe sampling is the most appropriate methodology available to evaluate potential worker 
exposure to these drugs (Kromhout et al. 2000; Fransman et al. 2004, 2005; Hon et al. 
2014)). Inhalation of aerosolized droplets or vapors, accidental hand-to-mouth ingestion 
following contact with contaminated surfaces, and needles or other sharps are also possible 
routes of exposure (NIOSH 2009). As stated by OSHA, in some cases skin absorption may 
be a more important route of exposure than inhalation, especially for non-volatile hazardous 
chemicals which remain on work surfaces for long periods of time and may not be noticed 
by the employees (https://www.osha.gov/dts/chemicalsampling/data/CH_235600.html). 
Although not a direct measurement of exposure, wipe samples can provide information 
about contamination on surfaces which may lead to dermal uptake by workers.
In general, it is assumed that dermal absorption is more likely to occur with drugs with a 
molecular weight of <500 Daltons and less likely for those >1000 Daltons (Bos and 
Meinardi 2000; Kimmel et al. 2011). In addition, lipid-soluble compounds more readily 
penetrate the skin than water-soluble ones and uptake may be enhanced by the use of carrier 
solvents. Although many antineoplastic drugs are relatively small molecules with molecular 
weights <500 Daltons, newer antineoplastic drugs, such as monoclonal antibodies, can have 
a molecular weight >40,000 Daltons, which presumably limit their potential for dermal 
uptake from contaminated surfaces (Connor and MacKenzie 2011; Alexander et al. 2014; 
King et al.). N, N-Dimethylacetamide and other solvents used in some drugs may pose an 
additional health risk and/or may facilitate drug penetration of the skin (Munro and 
Stoughton 1965).
McDevitt and colleagues at Johns Hopkins Hospital published the first study of surface 
contamination with antineoplastic drugs in the U.S (McDevitt et al. 1993). In that study, 
cyclophosphamide contamination was demonstrated in both the pharmacy and patient 
treatment areas. In the mid-1990s, several studies conducted in the Netherlands were 
published by Sessink and colleagues (Sessink et al. 1992, 1994a, b, 1997), which measured 
surface concentrations of several antineoplastic drugs by wipe sampling, including 
cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil. As in the U.S. study, 
surface contamination with these drugs was demonstrated in areas where they were prepared 
and administered to patients. The studies by Sessink also documented uptake of the drugs 
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based on their measurement in the urine of healthcare workers. Connor et al. (1999) 
measured surface contamination in three cancer hospitals in the United States and three in 
Canada. Their study documented surface contamination with cyclophosphamide, ifosfamide, 
and 5-fluorouracil in the pharmacy and patient treatment areas, and also in areas adjacent to 
the pharmacy. Since publication of these initial studies, world-wide reports have been 
published, demonstrating a universal issue with workplace surface contamination with 
antineoplastic drugs and uptake of the drugs by healthcare workers. In addition to surface 
wipe sampling, there have also been a limited number of dermal sampling studies reported 
in the literature (http://www.cdc.gov/niosh/topics/antineoplastic/). For this review, several 
relevant studies are discussed in order to describe a framework for wipe sampling for 
hazardous drugs in healthcare settings.
Although surface wipe sampling is the method of choice to evaluate surface contamination 
within healthcare settings for antineoplastic drugs, the analytical methodology used for 
surface wipe sampling and analytical laboratory analysis for antineoplastic drugs has varied 
considerably (Turci et al. 2003; Connor et al. 2016). This article reviews methodology 
currently being used for surface wipe sampling for hazardous drugs and discusses new 
applications of available technology that can be employed to make wipe sampling less 
expensive and to provide near real-time results for wipe sampling.
Surface wipe sampling methods
Methods for surface wipe sampling have been developed for a number of hazardous agents, 
such as lead (Brookhaven National Laboratory 1994), asbestos, pesticides, polychlorinated 
biphenyls (EPA 2007; ASTM 2010), methamphetamine (NIOSH 2011), antibiotics (Nygren 
et al. 2011), and similar methodology has been applied to sampling for hazardous drugs, 
primarily antineoplastic drugs (Connor et al. 2016). Although there are many variations in 
application, some approaches are common to all methods. Once a sampling scheme has been 
decided upon, it is necessary to determine if methods are available for the drugs of concern. 
Several laboratories offer analytical services for these drugs and often provide sampling kits 
for a battery of the more commonly used drugs. Sampling locations tend to be agreed upon, 
but the surface areas to be sampled can vary considerably, from a “standard” of 100 cm2 to 
500 cm2 or even larger (Connor et al. 2016). Typically, a commercially available template is 
used to delineate the wiping area. A suitable solvent is either applied directly to the surface 
to be sampled or applied to the sampling material. Sampling materials vary among tissues, 
filter paper, or special sampling swabs, although other sampling media may also work well. 
The surface is then wiped in a pre-determined pattern, usually in one direction and then 
perpendicular to that direction. The wiping process may then be repeated for the same 
location using a second wipe to ensure better recovery (B'Hymer et al. 2015). The wipes are 
then placed in labelled containers and shipped to the analytical laboratory for analysis. In 
some case, the samples may have to be shipped on dry ice to maintain drug stability.
Current Analytical methods for antineoplastic drugs
A comprehensive review of analytical methods by Turci et al. (2003) describes some of the 
sampling and analytical methods that have been employed. These have included gas 
chromatography (GC), high-performance liquid chromatography (HPLC), and ultra high-
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performance liquid chromatography (UPLC); all in combination with mass spectrometry 
(MS) or tandem mass spectrometry (MS/MS). Inductively coupled plasma mass 
spectrometry (ICP-MS) has been used for the analysis of total platinum in platinum-based 
drugs Turci et al. 2003). HPLC with mass spectrometry LC-MS/MS is the current method of 
choice for analysis of most antineoplastic drugs and does not require derivatization of the 
drug, as GC methods do (Sessink et al. 1992). Researchers using HPLC-MS/MS are 
reporting results in the pg/cm2 range. However, these methods are often very costly and it 
may take several weeks to obtain results using them. In addition, the number analytical 
laboratories in the U.S. that can perform these analyses is limited.
Analytical techniques for measurement of surface contamination by antineoplastic drugs 
such as HPLC–MS/MS are sensitive, specific, and accurate, but the initial equipment 
investment is high and a trained analytical chemist is required to operate the instrumentation, 
so these methods often cannot be used on a frequent basis due to cost (Pretty et al. 2012). 
Also, results from HPLC-MS/MS analyses are often obtained after a long delay, which may 
result in contamination existing for a long period of time before clean up can take place. 
Hence, these methods often cannot provide immediate feedback in developing work 
practices needed to lower exposure due to the time period between sample collection and 
obtaining the results of the analysis. Immunochemical techniques provide an opportunity for 
more cost-effective routine measurements and can provide direct reading near real-time on-
site measurements.
Immunochemical technique for simultaneous detection of drug surface contamination by 
multiple drugs
A fluorescence covalent microbead immunosorbent assay (FCMIA) for performing multiple 
immunochemical determinations simultaneously has been developed by Luminex 
Corporation. (Fulton et al. 1997, Oliver et al. 1998). FCMIA combines several classical 
methodologies: immunoassays, microspheres, and flow cytometry technology. In FCMIA, 
immunoassays are performed on sets of solid support 5.6 μm microspheres with different 
characteristic internal fluorophores that allow multiple assays to be performed 
simultaneously (multiplexing). FCMIA has predominantly been used for multiple protein 
and nucleic acid analytes such as multiple antibodies in serum (Biagini et al. 2003) multiple 
cytokines in serum (Bower et al. 2009), and multiple RNA and DNA viruses in patient 
samples. (Ginocchio et al. 2009). FCMIA assays are simple to set up and the instrumentation 
requires limited training to operate. NIOSH has developed an assay and sampling technique 
capable of evaluating multiple drugs of abuse on surfaces using competitive FCMIA (Smith 
et al. 2010), which has been used for exposure assessments in law enforcement evidence 
vaults where relatively high surface levels were observed in the studies (King et al. 2013; 
Fent et al. 2012).
A FCMIA has been demonstrated for use in the simultaneous measurement of multiple 
antineoplastic drugs (Smith et al. 2016). The antineoplastic drug assay uses a competitive 
assay format similar to the drugs of abuse FCMIA assay, where drug in solution competes 
with a microsphere bound drug–BSA conjugate for an anti-drug antibody. This results in 
less antidrug antibody being bound to the microsphere at higher drug concentrations. The 
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anti-drug antibody bound to the microsphere is detected with a labeled secondary antibody 
(biotin labeled anti-mouse IgG, (Pierce Biotechnology, Inc., Rockford, IL), which in turn 
binds a fluorescent label (streptavidin R-PE, Molecular Probes, Eugene, OR). Thus, the 
streptavidin R-PE fluorescent signal from the microsphere decreases with increasing drug 
concentration (Smith et al. 2016). The surface is sampled using a swab wetted in wash buffer 
(PBS-0.1% tween). The sampling is done by carefully wiping the surface with the wetted 
swab in one direction with an overlapping pattern, then repeating the same wiping pattern in 
a direction perpendicular to the first direction, and finally repeating the original wiping 
pattern. The swab is then placed in a vial containing 1 ml of storage/blocking buffer 
(PBS-1%BSA) and the swab is extracted with vigorous shaking for 2 min. The resulting 
solution is run in the assay without any further dilution.
In field applications, there was no significant cross-reactivity between these drugs at the 
ranges studied, indicated by a lack of response in the assay to potentially competing analytes 
(Smith unpublished data). The limit of detection (LOD) for the three drugs are listed in 
Table 1. The main use of this assay would be for screening surfaces in pharmacies, patient 
treatment areas, and other areas in healthcare facilities for contamination by antineoplastic 
drugs. Of special interest are pharmacy areas such as biological safety cabinets (BSCs) or 
compounding aseptic containment isolators (CACIs) used for drug preparation as well as 
nursing areas where drugs are administered to patients. Instrumental methods are more 
sensitive and specific than this assay for several of the drugs (e.g. 5-FU), but this assay is 
simple and could be set up to be performed at the worksite to provide more timely results. 
The components of the assay could be supplied as a kit that requires limited training to use. 
Use of this assay may provide a lower cost method for routine application.
It would be desirable for the FCMIA assay to screen for contamination for a wider array of 
drugs. This would require the development of antibodies and drug–protein conjugates for the 
additional drugs, which is a limitation of the assay. Also, cross-reactivity between the drugs 
being measured, as well as other drugs that might be present, would have to be assessed. The 
addition of other drugs would result in minimal increases in the time to perform the assay 
and the FCMIA assay could be used for more drugs at a relatively low cost.
Onsite detection techniques for drug surface contamination based on lateral flow 
immunoassay
Direct reading, field portable monitors to measure antineoplastic drugs on surfaces also can 
be used to help reduce potential exposure of healthcare workers to these drugs. Ideally, 
monitors need to be portable, near real time, sensitive, and easy to use. Monitors based on 
lateral flow immune assay (LFIA) fulfill the requirements of portability, sensitivity, rapid 
response, and ease of use. Lateral flow assays are used in many consumer products such as 
pregnancy tests and are being used in many point-of-care assays for clinical use 
(marketsandmarkets.com 2016). The lateral flow assay cassettes typically have two lines, a 
test line which varies in intensity with the concentration of analyte and a control line which 
is relatively constant for all samples and has been mainly used to assure that the cassette is 
working properly (Sajid et al 2015).
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Lateral flow assay for antineoplastic drug contamination—The development of 
LFIAs for antineoplastic drugs was based on prior work done by NIOSH to detect 
methamphetamine contamination on surfaces (Snawder et al. 2011). The methamphetamine 
lateral flow cassette along with components for the sampling method is commercially 
available as a kit from SKC Inc (MethChek 50, SKC Inc., Eighty Four, PA), which uses 
complete disappearance of the test line as the end point for detection. The methamphetamine 
kit has been used extensively by first responders such as police to evaluate contamination in 
sites where methamphetamine labs have been located (Hudson et al. 2008). In a further 
study of the methamphetamine lateral flow cassettes, comparison of the control line and test 
line was used as a visual end point and the methamphetamine cassettes were read with an 
electronic lateral flow reader (Smith et al. 2015). Use of line comparison or an electronic 
reader results in a more sensitive measurements as well as semi-quantitative evaluation of 
contamination.
Based on success of the lateral flow methamphetamine detection kit, NIOSH investigated 
the development of lateral assays for antineoplastic drugs. The first assay developed was for 
5-FU (Smith et al. 2015). The wiping pattern was identical to that used in FCMIA. A cotton 
swab wetted in sampling buffer (in this case PBS- 1% tween) was used and the swab wass 
extracted in 1 ml sampling buffer. For the 5-FU cassette, line comparison was used as the 
visual endpoint (Figure 1) since complete disappearance of the test line would have resulted 
in an end point that was less sensitive than desired. The cassette was also evaluated using the 
electronic lateral flow reader. The 5-FU assay was evaluated by spiking ceramic, vinyl, 
composite, stainless steel, and glass surfaces of 100 cm2 area with 5-FU masses of 0, 5, 10, 
25, 50, and 100 ng. The 5-FU cassette is capable of detecting 10 ng/100 cm2 (0.1 ng/cm2) 
using the electronic reader and 25 ng/100 cm2 (0.25 ng/cm2) using the visual line 
comparison method for the surfaces studied. Using measurements from the electronic lateral 
flow reader, the response from 0-100 ng/cm2 was fitted using the ratio of the control to the 
test line such that the cassette response could be used to predict the loading over this 
concentration range. The response of the cassettes was compared to LC-MS/MS results for 
the same samples for validation and there was good correlation of the two methods but the 
slope of the plots of the recovered mass from the 5-FU lateral flow measurement versus that 
for the LC-MS/MS varied from about 0.43 to 1.07 depending on the surface studied and the 
mass loading on the surface. In addition to 5-FU, lateral flow assays have been developed for 
paclitaxel and doxorubicin. The paclitaxel assay detected 50-100 ng/100 cm2, so it was less 
sensitive than desired but could be used at higher levels of contamination. The doxorubicin 
assay detected as low as 10 ng/100 cm2 but had limited range of response, low line intensity, 
and longer development time. Our commercial partner has produced an improved 
doxorubicin antibody and doxorubicin protein conjugate in order to develop an improved 
assay which is now being tested.
The 5-FU lateral flow assay has been used to evaluate contamination in a limited number of 
hospital pharmacy and patient treatment areas in a pilot study and has agreed with 
measurement from LC-MS/MS for most of the samples taken. Ongoing evaluations to 
provide data for a more comprehensive comparison of the lateral flow assay with LC-
MS/MS are underway. A large multinational medical equipment manufacturer has shown 
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interest in the commercial development of the lateral flow assay and has developed an 
improved assay for doxorubicin which uses a portable reader that the manufacturer 
developed.
Future Perspectives
Although the methodology for surface sampling is currently only available for a limited 
number of antineoplastic drugs, methods can be developed for other drugs depending on the 
availability of antibodies to them. Both LFIA and FCMIA have proven effective in other 
uses and settings (Biagini et al. 2003; Smith et al. 2010, 2015) and their applicability to 
measuring surface contamination with antineoplastic drugs at low levels has been 
demonstrated (Smith et al. 2015, 2016).
Conclusions
Surface wipe sampling is currently used to evaluate workplace contamination with 
antineoplastic drugs in healthcare and other settings where the drugs may be present. Using 
LC-MS/MS, surface levels of a few pg/cm2 can be measured. However, this method is costly 
and it may take a few weeks for the results to be reported to the facility, thus delaying 
necessary cleaning procedures and changes in work practices and engineering controls. In 
addition, most healthcare facilities do not have the capability to perform these assays in-
house and must outsource the analyses. A simple, sensitive near real-time method to 
measure these drugs on work surfaces would enable healthcare workers and health and 
safety personnel to perform these measurements and obtain immediate results. Therefore, 
the results of routine cleaning or for cleaning a spill could be obtained within minutes 
instead of days or weeks.
USP General Chapter <800> recommends performing baseline wipe sampling for hazardous 
drugs and periodically afterwards (every six months or as often as needed) (USP 2016). A 
battery of a relatively small number of available assays that could provide near real-time 
values for surface contamination would be beneficial to many healthcare other facilities 
where hazardous drugs are present.
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Figure 1. 5-Fluorouracil lateral flow assay cassettes with varying relative test line and control 
line intensities
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Table 1
LOD and LOQ using FCMIA
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